Identificador persistente para citar o vincular este elemento: http://hdl.handle.net/10553/46590
Campo DC Valoridioma
dc.contributor.authorSolé-Violán, Jordien_US
dc.contributor.authorRodríguez de Castro, Felipeen_US
dc.contributor.authorGarcía-Laorden, M. Isabelen_US
dc.contributor.authorBlanquer, Joséen_US
dc.contributor.authorAspa, Javieren_US
dc.contributor.authorBorderías, Luisen_US
dc.contributor.authorBriones, M. Luisaen_US
dc.contributor.authorRajas, Olgaen_US
dc.contributor.authorMartín-Loeches Carrondo, Ignacioen_US
dc.contributor.authorMarcos-Ramos, José Albertoen_US
dc.contributor.authorFerrer Agüero, José Maríaen_US
dc.contributor.authorGarcia-Saavedra, Ayozeen_US
dc.contributor.authorFiuza, M. Doloresen_US
dc.contributor.authorCaballero-Hidalgo, Aracelien_US
dc.contributor.authorRodriguez-Gallego, Carlosen_US
dc.date.accessioned2018-11-23T06:05:27Z-
dc.date.available2018-11-23T06:05:27Z-
dc.date.issued2010en_US
dc.identifier.issn0954-6111en_US
dc.identifier.urihttp://hdl.handle.net/10553/46590-
dc.description.abstractBackground: Several studies have investigated single nucleotide polymorphisms (SNP) in candidate genes associated with susceptibility, severity or outcome in patients with community-acquired pneumonia (CAP) with conflicting results. Methods: Multi-centre, prospective observational study. We studied 1162 white Spanish patients with CAP and 1413 controls. Severe forms of sepsis were recorded in 325 patients. Subjects were genotyped for the following polymorphisms: TNF -238 and -308, LTA +252, IL6 -174, IL1RN 86bp variable number of tandem repeats and TNFRSF1B+676 (TNFR2 M196R). Results: No significant differences in genotype or allele frequencies were seen among patients and controls. We did not find any association between TNF, LTA, IL6 and IL1RN polymorphisms with disease severity or outcome. Analysis of 28-day mortality showed a significant difference in the distribution of TNFRSF1B+676 G/T genotypes (p=0.0129). Sequential Kaplan-Meier survival analysis of TNFRSF1B+676 G/T polymorphism showed a protective role of the GT genotype. Cox regression analysis adjusted for age, gender, hospital of origin and comorbidities showed that patients with GT genotypes had lower mortality rates compared to patients with GG or TT genotypes (p=0.02; HR 0.53; 95% CI 0.31-0.90 for 90-day survival; p=0.01; HR 0.41; 95% CI 0.21-0.81 for 28-day survival and p=0.049; HR 0.48; 95% CI 0.23-0.997 for 15-day survival). Conclusions: Our study does not support a role for the controversial studied polymorphisms of the TNF, LTA, IL6 and IL1RN genes in the susceptibility or outcome of CAP. A protective role of heterozygosity for the functionally relevant TNFRSF1B+676 polymorphism in the outcome of CAP was observed.en_US
dc.languageengen_US
dc.relation.ispartofRespiratory Medicineen_US
dc.sourceRespiratory Medicine [ISSN 0954-6111],v. 104, p. 440-447en_US
dc.subject32 Ciencias médicasen_US
dc.subject320508 Enfermedades pulmonaresen_US
dc.subject320102 Genética clínicaen_US
dc.subject.otherCommunity-acquired pneumoniaen_US
dc.subject.otherGenetic polymorphismsen_US
dc.subject.otherSusceptibilityen_US
dc.subject.otherOutcomeen_US
dc.titleGenetic variability in the severity and outcome of community-acquired pneumoniaen_US
dc.typeinfo:eu-repo/semantics/articleen_US
dc.typeArticleen_US
dc.identifier.doi10.1016/j.rmed.2009.10.009en_US
dc.identifier.scopus2-s2.0-76549131218-
dc.contributor.authorscopusid24391710100-
dc.contributor.authorscopusid55942667000-
dc.contributor.authorscopusid6506073949-
dc.contributor.authorscopusid7004176630-
dc.contributor.authorscopusid6602555827-
dc.contributor.authorscopusid16168865800-
dc.contributor.authorscopusid7006010004-
dc.contributor.authorscopusid6505890335-
dc.contributor.authorscopusid25823917100-
dc.contributor.authorscopusid24390906800-
dc.contributor.authorscopusid16063032700-
dc.contributor.authorscopusid13408676500-
dc.contributor.authorscopusid56698082300-
dc.contributor.authorscopusid24829379200-
dc.contributor.authorscopusid6602114379-
dc.description.lastpage447en_US
dc.description.firstpage440en_US
dc.relation.volume104en_US
dc.investigacionCiencias de la Saluden_US
dc.type2Artículoen_US
dc.description.numberofpages8en_US
dc.utils.revisionen_US
dc.date.coverdateNoviembre 2010en_US
dc.identifier.ulpgcen_US
dc.description.jcr2,525
dc.description.jcrqQ2
dc.description.scieSCIE
item.grantfulltextnone-
item.fulltextSin texto completo-
crisitem.author.deptGIR IUIBS: Patología y Tecnología médica-
crisitem.author.deptIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.deptDepartamento de Ciencias Médicas y Quirúrgicas-
crisitem.author.deptGIR IUIBS: Farmacología Molecular y Traslacional-
crisitem.author.deptIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.deptDepartamento de Ciencias Médicas y Quirúrgicas-
crisitem.author.orcid0000-0002-6812-2739-
crisitem.author.orcid0000-0002-4344-8644-
crisitem.author.parentorgIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.parentorgIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.fullNameRodríguez De Castro, Felipe Carlos B.-
crisitem.author.fullNameRodríguez Gallego, José Carlos-
Colección:Artículos
Vista resumida

Citas SCOPUSTM   

50
actualizado el 15-dic-2024

Citas de WEB OF SCIENCETM
Citations

45
actualizado el 15-dic-2024

Visitas

68
actualizado el 17-ago-2024

Google ScholarTM

Verifica

Altmetric


Comparte



Exporta metadatos



Los elementos en ULPGC accedaCRIS están protegidos por derechos de autor con todos los derechos reservados, a menos que se indique lo contrario.